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Abstract
The past 10 years have seen the description of families of
receptors that drive proinflammatory cytokine production in
infection and tissue injury. Two major classes have been examined
in the context of inflammatory joint disease – the Toll-like receptors
(TLRs) and NOD-like receptors (NLRs). TLRs such as TLR2 and
TLR4 are being implicated in the pathology of rheumatoid arthritis,
ankylosing spondylitis, lyme arthritis and osteoarthritis. Nalp3 has
been identified as a key NLR for IL-1β production and has been
shown to have a particular role in gout. These findings present new
therapeutic opportunities, possibly allowing for the replacement of
biologics with small molecule inhibitors.
Introduction
Proinflammatory cytokines such as TNF, IL-6 and IL-1 have
proven to be excellent therapeutic targets for diseases such
as rheumatoid arthritis (RA). More recently, however, atten-
tion has focused on the mechanisms whereby these cyto-
kines are induced. In this regard there has been remarkable
progress in the elucidation of receptors that drive their
production as well as other inflammatory mediators. This
progress has led to a renaissance of interest in innate
immunity among immunologists, since these receptors also
sense microbial products to drive host defense.
Two particular classes – the Toll-like receptors (TLRs) and
NOD-like receptors (NLRs), which are pattern recognition
receptors (PRRs) – have been most extensively studied.
Certain TLRs (for example, TLR2, TLR4 and TLR9) and
certain NLRs (for example, Nalp3) have been implicated in
various inflammatory arthopathies. More recently evidence
has been presented that these TLRs and NLRs might also be
activated by noninfectious endogenous signals, making them
even more attractive as important drivers of cytokines in
diseases with no obvious infection.
In the present review we will summarise the current state of
knowledge in TLRs and NLRs, and also speculate on their
roles in the pathogenesis of autoinflammatory joint diseases.
Toll-like receptors
The past 10 years have seen over 11,000 papers published
on TLRs, which is a testament to the importance placed upon
them by inflammation biologists and immunologists. Ten TLRs
occur in humans, and the roles of nine of them (TLR1 to
TLR9) have been determined [1].
TLR2 senses lipopeptides from bacteria, with TLR1/2 dimers
sensing triacylated lipopeptides and TLR2/6 dimers sensing
diacylated lipopeptides. In addition, TLR2 also senses zymosan
from fungi. The structure of the TLR1/2 dimer has been solved
[2], as has the structure of TLR4 in complex with its ligand lipo-
polysacharide from Gram-negative bacteria that are presented
to TLR4 by MD2 [3]. TLR4 can also sense F protein from res-
piratory syncytial virus and glycerophosphatidylinositol anchors
from parasites [4,5]. This provides a receptor repertoire to
respond to all pathogens that infect humans.
The signaling pathways activated by TLRs have also been
worked out in great detail and involve the selective recruit-
ment of adapter proteins (MyD88, Mal, Trif and Tram) [6].
These lead to activation of NF-κB, which is a major response
to TLRs. Certain TLRs (TLR4 and nucleic acid-sensing TLRs)
can also engage with a pathway leading to the activation of
the transcription factor interferon regulatory factor-3. Both
NF-κB and interferon regulatory factor-3 are required for the
induction of a wide range of cytokines.
NOD-like receptors
NLRs are intracellular sensors of pathogen-associated or
endogenous danger-associated molecular patterns. The NLR
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family consists of 22 cytoplasmic proteins including the NOD
and NALP subfamilies, with the 14 NALPs representing the
largest subfamily. NLR family members share common
structural features, including a nucleotide binding domain
(nucleotide binding site or NACHT domain) central to the
molecule, flanked by a leucine rich-repeat domain at the C-
terminus and a caspase-recruitment domain and a pyrin
domain at the N-terminus.
The best characterised NLR is NALP3, which when activated
forms a large oligomer able to interact with intermediate
proteins ASC and Cardinal, creating a complex able to recruit
procaspase-1. Through an autocatalytic process, procaspase-1
is then activated – resulting in a multimeric structure termed
the inflammasome, which is able to induce maturation and
secretion of proinflammatory cytokines IL-1β and IL-18 [7].
Gain of function mutations in the NALP3 gene leading to
elevated levels of processed IL-1β cause hereditary periodic
fever syndromes in humans, including Mucke–Wells syn-
drome, chronic infantile cutaneous neurologic articular syn-
drome and familial cold-induced autoinflammatory syndrome
[8]. Fever, joint pain and systemic inflammation are common
features of these disorders and provided the first clue that the
inflammasome has a potential role in rheumatic diseases [9].
The effectiveness of IL-1β blockade (Anakinra) in treating
inherited periodic fever syndromes has transformed the
understanding and management of these disorders and has
implications for future therapies in rheumatic diseases.
Important links and synergies are evident between TLRs and
NLRs. TLRs are required to induce pro-IL1β, and the Nalps
then activate caspase-1 to process it, so both act in concert
for IL-1 production [10]. Another important aspect is the link
between these receptors and adaptive immunity. Nalp3 has
been shown to be a target for the adjuvant Alum, although
whether it is required for antibody production is less clear.
TLRs, however, are important for inducing the T-cell co-
stimulatory molecules CD80 and CD86. This is particularly
the case with TLR4, which achieves this via induction of IFNβ
[11]. B cells and T cells have also been shown to express
certain TLRs – TLR9 has been shown to induce B-cell
proliferation [12], whilst TLR2 has been shown to be present
on regulatory T cells and to activate them [13]. These kinds of
studies highlight the role of innate immunity in the adaptive
response, and the two responses are increasingly seen as
inter-linked.
Rheumatoid arthritis
There has been a longstanding hypothesis that infection plays
a role in the initiation of RA (Figure 1). Molecules of microbial
origin have been found in the joints of patients with RA
[14,15], where they can trigger inflammatory reactions
through PRRs. These inflammatory reactions damage the
host tissue, releasing molecules (danger signals) that can
activate the PRRs resulting in vicious cycles of inflammation.
This sterile inflammation induced by endogenous danger
signals released from the inflamed host tissue is thought to
lead to the pathological joint destruction associated with RA.
There is increasing evidence that TLRs, and more recently
NLRs, have a role in RA pathology.
Ospelt and colleagues comparatively analysed the expression
of TLRs in synovial tissues during the early and late stages of
RA, and found that TLR3 and TLR4 were elevated in both
early and late RA samples compared with samples from
osteoarthritis (OA) synovium [16]. These results concur with
studies from Brentano and colleagues, who also detected
elevated levels of TLR3 expression in RA synovial fibroblasts
over OA synovial fibroblasts [17]. Similarly, elevated levels of
TLR7 have also been detected in synovium from RA patients
compared with OA patients or healthy volunteers [18]. In
addition to synovial fibroblasts, differences in TLR expression/
activity have also been detected in macrophages isolated
from synovium of RA patients. Huang and colleagues dis-
covered elevated levels of TLR2 and TLR4 activity in
macrophages isolated from RA synovium compared with
control synovium [19]. Spontaneous production of proinflam-
matory cytokines and matrix metalloproteinases from RA
synovial membrane cultures has been shown to be inhibited
by overexpressing dominant negative constructs of Mal and
MyD88, essential adaptors molecules for TLR2 and TLR4
signaling [20].
A later study investigating the use of a novel TLR4 antagonist
has shown the most convincing evidence for TLR involvement
in RA, as shown in Figure 2 [21]. In this study, two mouse
models of RA were used to test a TLR4 antagonist for
efficacy. An IL1-receptor antagonist knockout model, where
the mice develop arthritis spontaneously, was run alongside a
collagen-induced arthritis model that requires the use of an
adjuvant containing TLR ligands. In both models the TLR4
antagonist showed impressive therapeutic effects. Another
study by the same group crossed TLR2, TLR4 and TLR9
knockout mice with the IL1-receptor antagonist knockout
mice that spontaneously develop arthritis [22]. Agreeing with
the results from their TLR4 antagonist study, Abdollahi-
Roodsaz and colleagues found that IL1rn–/–TLR4–/– animals
are protected against arthritis whereas IL1rn–/–TLR2–/–
animals develop a more severe arthritis – suggesting an anti-
inflammatory role for TLR2 in this model. A lack of TLR9 did
not affect the progression of arthritis. The anti-inflammatory
nature of TLR2 in the IL1-receptor antagonist knockout
models is in contrast to results obtained in a streptococcal
cell wall induced model of arthritis, where mice deficient for
TLR2 were shown to have a reduced severity of arthritis [23].
TLR4 has been shown to be involved in the chronic erosive
stage of arthritis in this model of disease [24].
As already mentioned, the role of TLRs in RA is believed to
be driven by inflammation in response to danger signals
(endogenous host cell molecules released from stressedcells) as well as TLR ligands of microbial origin. Similar to the
microbial TLR ligands, endogenous TLR ligands have been
found in the joints or serum of RA patients and their levels
have been correlated with disease activity scores [25]. These
ligands – including heat shock proteins, fibronectin, high-
mobility group box chromosomal protein-1 (HMGB1) and
breakdown products of heparan sulfate and hyaluronic acid –
activate TLR2, TLR4, or both. The most recent addition to the
growing list of endogenous TLR ligands is GP96 [26]. GP96
is a heat shock glycoprotein detected at high levels in RA
synovial tissues that is capable of activating TLRs. Like
HMGB1, this endogenous ligand has been shown to drive
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Figure 1
Signaling through pathogen-associated and damage-associated molecular patterns drives chronic inflammation in diseases like rheumatoid
arthritis. Bacterial DNA, peptidoglycans, muramyl dipeptide and viral molecules have been found in arthritic joints. These microbial pathogen-
associated molecular patterns (PAMPs) can drive inflammation through the membrane-bound (Toll-like receptor (TLR)) and cytosolic (NOD-like
receptor (NLR)) pattern recognition receptors (PRRs). The resulting release in inflammatory cytokines can drive the damage of host tissue releasing
damage-associated molecular patterns (DAMPs), such as high-mobility group box protein 1, GP96, heat shock proteins and ATP, which also
activate both types of PRR resulting in a vicious cycle of inflammation.
Figure 2
Treating spontaneous arthritis with a TLR4 antagonist suppresses the clinical and histological characteristics of arthritis. Abdollahi-Roodsaz and
colleagues have recently shown that treating collagen-induced arthritis (left-hand side) with a TLR4 antagonist suppresses the clinical and
histological characteristics of arthritis (right-hand side). Histological images of knee joints are shown, stained with hematoxylin and eosin. Arrow
indicates inflammatory cell influx and chondrocyte cell death. Image taken from [21]. Reproduced with permission of John Wiley and Sons.inflammation by signaling through both TLR2 and TLR4.
Considering the extensive evidence linking TLR signaling and
RA pathology, it is surprising that no TLR polymorphisms
have been identified involved in the susceptibility and severity
of RA [16,27,28].
While TLRs appear to be the principal PRRs implicated in RA
pathology, evidence is emerging that NLRs may also have a
role in RA. NOD1 and NOD2 have been shown to be
expressed in RA synovial tissue samples, and the microbial
ligand for NOD2, muramyl dipeptide, has been detected in
RA synovium [29,30]. Using NOD1 and NOD2 knockout
mice, Joosten and colleagues have shown a proinflammatory
role for NOD2 and an anti-inflammatory role for NOD1 in a
streptococcal cell wall induced model of arthritis [30].
Lyme arthritis and TLR2
Lyme arthritis is caused by infection with the tick-borne
spirochete  Borrelia burgdorferi. A subacute inflammatory
arthritis develops in 60% of individuals not treated at the time
of the tick bite, and is associated with invasion of the joint
tissue by spirochetes. Immune responses of the host toward
B. burgdorferi are predominantly mediated by the recognition
of proteins modified with tripalmitoyl-S-glyceryl-cysteine by
TLR2 [31]. TLR2 knockout mice have been shown to be
hyporesponsive to vaccination with lipopeptides, and hypo-
responsiveness in humans is linked with low levels of TLR1
expression [32]. In contrast to the studies in the TLR2
knockout mice, a polymorphism resulting in a nonfunctional
TLR2 receptor (Arg753Gln) in vitro has been shown to be
protective from the clinical symptoms of late-stage infection
with B. burgdorferi [33].
Systemic lupus erythematosus, Toll-like
receptors and the AIM2 inflammasome
Systemic lupus erythematosus (SLE) is a prototypic systemic
autoimmune disease, the cause of which has not yet been
fully elucidated. Immune complexes of autoantibodies to
chromatin and RNA protein particles (snRNP) are charac-
teristic of SLE and play an important role in the pathogenesis
of the disease. Increased levels of serum IFNα have been
found in many patients with SLE, and these levels correlate
with disease severity and disease markers such as the DNA
autoantibodies. Evidence for the crucial role of type 1
interferon in the pathology of lupus comes indirectly from
findings that patients with nonautoimmune disorders treated
with recombinant IFNα produce autoantibodies to DNA and
develop clinical syndromes that resemble SLE [34,35].
There is good evidence that TLRs are involved in SLE. TLR9-
expressing B cells are expanded in SLE patients with active
disease, and this is correlated with levels of autoantibodies
against DNA [36]. Activation of endosomal TLRs is believed
to drive the elevated levels of IFNα that promote and maintain
SLE disease progression. Nephritis is a condition associated
with SLE, and in a murine model of the disease (MRLlpr/lpr)
immunisation with unmethylated CpG, an exogenous TLR9
ligand, aggravates the condition [37]. This is consistent with
observed association of lupus flares with viral infection. Using
TLR7 and TLR9 oligonucleotide-based inhibitors, mammalian
DNA and RNA in the form of immune complexes from SLE
patient serum have been shown to act as endogenous
ligands for TLR7 and TLR9, respectively [38]. In lupus-prone
(NZB x NZW)F1 mice that spontaneously develop symptoms
similar to human lupus, administration of a TLR7/TLR9 dual
oligonucleotide inhibitor showed efficacy at suppressing the
production of autoantibodies, reducing kidney damage and
increasing survival of treated mice [39]. In the MRLlpr/lpr lupus
model, mice deficient for MyD88 failed to produce DNA
autoantibodies [40]. In the same lupus animal model, TLR7
deficiency has shown reduced autoimmune disease as
expected, while TLR9 deficiency resulted in exacerbated
autoimmune disease [41].
The pathogenic rather than protective effect observed in the
TLR9 knockout in the MRLlpr/lpr lupus mouse model does not
correlate with the earlier in vitro studies linking TLR9
activation to disease progression. It has been suggested that
human–mouse differences in the expression, distribution and
functional response of TLR7 and TLR9, as well as drawbacks
in the animal model used, may explain the pathogenic effect
observed in the TLR9 knockout MRLlpr/lpr mouse model [42].
Three studies have failed to correlate a certain set of
polymorphisms in TLR9 with SLE [43-45]; however, a
Japanese group recently identified two alleles that
downregulated TLR9 expression in a reporter assay but are
associated with increased SLE susceptibility [46]. This
linkage would indicate that the TLR9 knockout data from the
MRLlpr/lpr mice may be correct and that TLR9 has an anti-
inflammatory function in SLE.
It remains to be seen whether endosomal TLR agonist or
antagonists will be beneficial for the treatment of SLE;
however, endosomal TLR signaling certainly appears to be
involved in SLE pathology. Interestingly a polymorphism in
Mal, the signaling adaptor used by TLR2 and TLR4, has been
shown to be protective against SLE [47]. This polymorphism
attenuates Mal signal transduction, which would diminish
signaling through TLR2 and TLR4 [48]. Interestingly, HMGB1-
containing DNA immune complexes that have been shown to
bind RAGE on plasmactytoid dendritic cells and B cells [49]
have recently been shown to induce proinflammatory cytokine
production in macrophages in a TLR2-dependent manner
[50]. These results indicate that there may be a more complex
interplay between cell surface TLRs, their adaptors and
endosomal TLRs in the pathology of SLE.
A cytoplasmic DNA-sensing inflammasome has been
described more recently that is NALP3 independent. Absent
in melanoma-2 (AIM2) is an interferon-inducible HIN200
family member that binds DNA through the HIN domain and
has a pyrin domain that interacts with ASC to activate NF-κB
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recognition of cytoplasmic dsDNA in human macrophages
[51-53]. SLE is characterised by elevated levels of interferon
and by the presence of DNA:antibody complexes. In
addition, genetic mapping studies have identified a
susceptibility locus for SLE that contains the AIM2 gene,
raising the possibility that AIM2 has a role to play in the
pathology of SLE. Further studies are required to fully
elucidate any link between AIM2 and SLE. The identification
of AIM2 may in addition help to explain the results observed
by Kawane and colleagues, who observed a TLR-
independent polyarthritic phenotype in mice deficient for
DNaseII and IFNIR as a consequence of the inability of
macrophages to efficiently degrade cytosolic DNA [54].
Ankylosing spondylitis, TLR2 and TLR4
Ankylosing spondylitis is a multifactorial and polygenic
inflammatory rheumatic disease with a poorly understood
pathophysiology. Apart from HLA, other genes are likely to
play a role in disease susceptibility and indigenous bacteria
also appear to be involved in the pathology. This suggests
that both adaptive and innate immune responses are required
for disease progression. Expression studies looking at the
CD4+CD28null T-cell populations from ankylosing spondylitis
patients have shown that TLR2 and TLR4 levels are
increased and that this effect can be reduced by therapeutic
blockade of TNFα [55]. Polymorphisms in TLR4 have been
described and there are several studies that have looked at the
association between these polymorphisms and susceptibility to
ankylosing spondylitis. There is good evidence for a link
between both Asp299Gly and Thr399Ile polymorphisms and
ankylosing spondylitis [56], but no link with the Asp896Gly
polymorphism [57]. The functional consequences of these
polymorphisms and the mechanistic link to ankylosing
spondylitis remain to be established. The S180L polymorphism
in TIRAP/Mal that has been shown to be protective against
SLE [47] has no association with axial spondyloarthritis [58].
Psoriatic arthritis
Psoriatic arthritis is an inflammatory arthritis associated with
psoriasis in which the CD8+ T cell plays a pivotal role. The data
on TLRs in psoriatic arthritis are restricted to a few studies of
expression levels of TLR2 and TLR4. Candia and colleagues
have shown that TLR2 expression was increased in immature
dendritic cells from patients with psoriatic arthritis, although
mature dendritic cells did not show statistically significant
differences [59]. No effect was seen on TLR4 expression.
Conversely, Raffeiner and colleagues looked at CD4+CD28null
T cells and showed an increase in surface levels of TLR4 but
no effects on TLR2 [55]. Further detailed analysis of TLRs in
psoriatic arthritis is required to better understand whether there
is a role in the pathogenesis of the disease.
Gout, pseudogout, TLR2 and Nalp3
Gout and pseudogout are crystal-induced arthropathies, gout
being the most common autoinflammatory arthritis with
increasing incidence over the past decade [60]. Gout is
characterised by elevated serum urate and recurrent attacks of
intra-articular crystal deposition of monosodium urate, whereas
pseudogout is associated with calcium pyrophosphate
dihydrate crystals and has a poorly understood pathophysiology.
Uric acid crystals stimulate dendritic cell maturation, enhance
antigen-specific immune responses and directly activate T
cells leading to elevated levels of CD70 [61]. The role of the
innate immune system in gout has now been firmly
established with the realisation that the uptake of mono-
sodium urate crystals by monocytes involves interactions with
TLR2 and CD14 [62] and that intracellularly monosodium
urate crystal-induced inflammation is mediated by the NALP3
inflammasome [63]. The role of the NALP3 inflammasome
was confirmed in a monosodium-urate-induced peritonitis
mouse model that mimics an acute gout attack. Intra-
peritoneal injection of monosodium urate induces recruitment
of neutrophils, and this effect was abrogated when either
Anakinra or an anti-IL-1R antibody was co-administered with
monosodium urate [63]. This monosodium-urate-induced
mouse gout model clearly establishes the role of IL-1 in gout
and led to an open-label study of Anakinra in 10 patients with
gout that could not tolerate or had failed standard anti-
inflammatory therapies. All patients received Anakinra daily for
3 days and all showed rapid positive responses with no
adverse effects observed [64]. In addition, there is one report
of Anakinra delivering a positive effect in a steroid-resistant
pseudogout patient [65].
Osteoarthritis and Toll-like receptors
Synovial inflammation is increasingly recognised as an impor-
tant pathophysiological process in OA, and endogenous
ligands released as a consequence of synovial and cartilage
catabolism (for example, fibronectin and hyaluronan
fragments) are likely to be recognised by PRRs [66].
Histology and expression studies using isolated chondro-
cytes and cartilage have shown that human articular chon-
drocytes predominantly express TLR1, TLR2, TLR3, TLR4
and TLR5 [67-69]. Expression of TLR2 and TLR4 is elevated
in OA particularly at sites of lesions in cartilage [67,69].
Treatment of isolated cells with inflammatory cytokines and
fibronectin proteolytic fragments results in increased expres-
sion of TLR2, and culture in the presence of TLR1/2 or
TLR2/6 ligands but not TLR3 ligands results in elevated
levels of matrix metalloproteinases and significantly increased
collagenolysis and aggrecanolysis [67,69].
OA is also associated with crystal deposition in synovial fluid –
in particular, calcium pyrophosphate dihydrate and basic
calcium phosphate [70], as well as hydroxyapatite [71] and
silicon dioxide [72]. The physiological relevance of crystals to
disease pathology is keenly debated but it seems probable
that recognition of these crystals by the inflammasome will
contribute to local inflammation in the joint [73].
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opportunities
The roles of TLRs and Nalp3 in arthropathies are becoming
clearer and they remain exciting therapeutic options. One
interesting example is in aseptic loosening that occurs in
10% of joint replacements, resulting in revision surgery.
Evidence is emerging to suggest that aseptic loosening of
total joint replacements is driven through implant debris
activation of the inflammasome leading to locally elevated
levels of inflammatory cytokines [74]. More obviously Nalp3,
TLR2 and TLR4 are attractive targets for RA and OA, whilst
TLR7 and/or TLR9 and AIM2 represent therapeutic potentials
for joint inflammation in SLE.
There has been considerable focus on identification of small
molecule agonists and antagonists of TLRs over the past 5
years, with several successful examples now undergoing
clinical evaluation. If the preclinical observations described in
the present review [21,39] translate to the clinic, then
inhibition of TLRs and NLRs using small molecules may
provide viable replacements for current biologic agents. In
any event, the hope is that these new insights into innate
immunity will ultimately translate into better therapies for
inflammatory arthropathies that continue to represent a major
burden on humanity.
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